Loading...
•
Mar 31, 2021
SIGA Technologies Q1 2021 Earnings Report
SIGA Technologies' financial performance was mixed, with increased international sales offset by operating losses.
Key Takeaways
SIGA Technologies reported a positive trend in international sales, with approximately $3 million of oral TPOXX® delivered to the Public Health Agency of Canada in the first quarter. Total revenues increased to $4.8 million compared to $2.6 million in the same period last year. The company's operating loss was $(2.0) million, and its net loss was $(0.8) million, with a diluted loss per share of $(0.02).
Total revenues increased to $4.8 million compared to $2.6 million year-over-year.
Approximately $3 million of oral TPOXX® was delivered to the Public Health Agency of Canada in Q1.
Operating loss was $(2.0) million, an improvement from $(4.0) million in the prior year.
The company filed a new drug application with the FDA for the intravenous formulation of TPOXX.
Revenue by Segment
Forward Guidance
SIGA Technologies anticipates BARDA sales to be concentrated in the second half of 2021, while international sales are expected to be concentrated in the first half of 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...